CASI Pharmaceuticals Announces First Patient Dosed In Phase 2 Trial For ENMD-2076 In Fibrolamellar Carcinoma (FLC)

The US Food and Drug Administration (FDA) has granted approval for Roche’s Gazyva/ Gazyvaro (obinutuzumab) to treat adult patients with active lupus nephritis (LN) who are on...

Aspire Pharma, a rapidly growing UK-based specialty generics business, has announced the acquisition of Charlwood Pharma, a privately-owned company specializing in the research and development of nich...

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

FDA approves Glaukos’ Epioxa as incision-free corneal disease treatment